Dr. Robin L. Dalal, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Medical College of Georgia School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 148
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Medical College of Georgia School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
TN license 0000049030 -
Internal Medicine Physician
TN license TN0000049030
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Vanderbilt University Medical Center Nashville, TN
Medical groups
- Vanderbilt University Medical Center (3,567 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 148
- Services billed
- 242
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Biopsy of large bowel using a flexible endoscope | 58 | 57 |
| Established patient office or other outpatient visit, 30-39 minutes | 37 | 30 |
| Established patient office or other outpatient visit, 40-54 minutes | 25 | 20 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 21 | 21 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 16 | 16 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Stelara (ustekinumab) | 94 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Nashville, TN | 77 |
| Skyrizi On-Body (risankizumab-rzaa) | 50 |
| Rinvoq (upadacitinib) | 37 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Nashville, TN | 35 |
| Xeljanz (tofacitinib citrate) | 33 |
| Omeprazole Other prescribers in Nashville, TN | 29 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Nashville, TN | 25 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Nashville, TN | 22 |
| Entyvio (vedolizumab) | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 13 payments worth $6,748 in total to this clinician.
| AbbVie Inc. | $6,386 |
|---|---|
| Janssen Biotech, Inc. | $143 |
| Lilly USA, LLC | $117 |
| Janssen Scientific Affairs, LLC | $65.10 |
| Takeda Pharmaceuticals U.S.A., Inc. | $37.20 |
| Consulting Fee | $6,300 |
|---|---|
| Food and Beverage | $448 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Jun 3, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $3,500 |
| AbbVie Inc. Jun 26, 2025 | Consulting Fee | $2,100 |
| AbbVie Inc. Dec 16, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $700 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $55,586 in research payments for these studies, mostly to the institutions running them.
- M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
AbbVie Inc. - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
AbbVie Inc. · Active, not recruiting · NCT03398135 - Prospective study on surgical interventions in complex fistulizing conditions (cd-cpaf, cd-rvf, ccf) in the us, canada, and eu
Takeda Pharmaceuticals U.S.A., Inc. - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.